TargetBeta
DPP4
dipeptidyl peptidase 4 · also DPPIV, CD26, ADCP2 · CD molecules
6 programs in company-led studies act on DPP4, from 6 companies: 0 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| sitagliptinrule | Merck | phase 4 | 1232 running | – | ChEMBL |
| Linagliptinrule | Boehringer Ingelheim | phase 4 | 961 running | – | NCIt |
| anagliptinrule | JW Pharmaceutical | phase 4 | 61 running | – | NCIt |
| gemigliptinrule | LG Chem | phase 4 | 300 running | – | NCIt |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 20 running | SLC5A2 | NCIt |
| cofrogliptinrule | Haisco Pharmaceutical Group | no phase | 11 running | – | the studies' text |
Also acted on by the same programs
Conditions their studies are in
- Diabetes Mellitus, Type 2, 6 programs
- Diabetes Mellitus, 2 programs
- Renal Insufficiency, 2 programs
- Carcinoma, Non-Small-Cell Lung, 1 program
- Esophageal Neoplasms, 1 program
- Glucose Intolerance, 1 program
- Hepatic Insufficiency, 1 program
- Hypertension, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 31, 2027anagliptin · JW Pharmaceutical · phase 4 · NCT07442006
- Jun 30, 2027cofrogliptin · Haisco Pharmaceutical Group · no phase · NCT07122102
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.